Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released May 8, 2024, after the close
10-Q filed May 8, 2024, 38 days after period end · 0001171843-24-002682
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $29.02M | $37.92M | $36.69M | $34.29M |
| Net Income | -$4.51M | -$10.35M | -$2.93M | $2.84M |
| EPS Diluted |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$0.31 |
| -$0.71 |
| -$0.20 |
| $0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
